About: http://data.cimple.eu/news-article/ae6f888aee2058e864d61a6908ea5b84cf1b9b4b4348764a42b6eb5f     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The EU is about to start negotiations with a single pharmaceutical company to secure up to 1.8 billion doses of a "second generation" mRNA vaccine to combat future variants, a European Commission source said. The upcoming deal aims to have deliveries made on a monthly schedule starting late this year and going into 2023, the source told AFP. It is part of the commission's preparedness plan to handle "the next stages" of the pandemic as the coronavirus continues to mutate, said the source, who is familiar with the approach taken by commission chief Ursula von der Leyen. The source would not say which "sole supplier" would be tapped, but did not demur asked if it was BioNTech/Pfizer, which has already agreed to bring forward deliveries to the EU of its first-generation mRNA vaccine. "We want a big volume" of doses, "we want a firm contract for 900 million doses and an option for the same again", the source said. The extra doses would greatly increase the EU's access to vaccines to fight the coronavirus pandemic by going beyond the 2.6 billion doses of various "first-generation" vaccines already secured for this year and next. They would address growing concerns globally that the current vaccines deployed can have their effects dampened by some variants, as appears to already be the case with strains first detected in South Africa and Brazil. "There will be a delivery obligation" for the extra doses, the source emphasised. That implicitly pointed to problems the commission has had with AstraZeneca to have it deliver contracted doses of its vaccine -- an adenovirus vaccine different from the mRNA types produced by BioNTech/Pfizer and Moderna. The next-generation mRNA vaccine the commission is looking to buy "has to cover all the variants that could emerge" -- and "with a production within Europe and a priority for Europe", the source said. jug/rmb/dc/jv
schema:headline
  • EU poised to secure 1.8 bn 2nd-generation vaccine doses
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software